Product
Zinlirvimab
Aliases
GS-2872
2 clinical trials
2 indications
Indication
HIV InfectionsIndication
HIV-1 InfectionClinical trial
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 InfectionStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 InfectionStatus: Completed, Estimated PCD: 2023-04-18